You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

LANTHANUM CARBONATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lanthanum Carbonate, and when can generic versions of Lanthanum Carbonate launch?

Lanthanum Carbonate is a drug marketed by Barr, Invagen Pharms, and Natco Pharma Ltd. and is included in three NDAs.

The generic ingredient in LANTHANUM CARBONATE is lanthanum carbonate. There are nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the lanthanum carbonate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lanthanum Carbonate

A generic version of LANTHANUM CARBONATE was approved as lanthanum carbonate by NATCO PHARMA LTD on August 11th, 2017.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LANTHANUM CARBONATE?
  • What are the global sales for LANTHANUM CARBONATE?
  • What is Average Wholesale Price for LANTHANUM CARBONATE?
Drug patent expirations by year for LANTHANUM CARBONATE
Drug Prices for LANTHANUM CARBONATE

See drug prices for LANTHANUM CARBONATE

Recent Clinical Trials for LANTHANUM CARBONATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medical University of LodzPhase 4
Medical Universtity of LodzPhase 4
Universitair Ziekenhuis BrusselPhase 3

See all LANTHANUM CARBONATE clinical trials

Pharmacology for LANTHANUM CARBONATE
Drug ClassPhosphate Binder
Mechanism of ActionPhosphate Chelating Activity
Paragraph IV (Patent) Challenges for LANTHANUM CARBONATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FOSRENOL Oral Powder lanthanum carbonate 750 mg and 1000 mg 204734 1 2015-11-25
FOSRENOL Chewable Tablet lanthanum carbonate 500 mg, 750 mg and 1000 mg 021468 3 2008-10-27

US Patents and Regulatory Information for LANTHANUM CARBONATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Barr LANTHANUM CARBONATE lanthanum carbonate TABLET, CHEWABLE;ORAL 090977-003 Jan 27, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Natco Pharma Ltd LANTHANUM CARBONATE lanthanum carbonate TABLET, CHEWABLE;ORAL 090978-003 Aug 11, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Invagen Pharms LANTHANUM CARBONATE lanthanum carbonate TABLET, CHEWABLE;ORAL 206868-003 Jan 24, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Natco Pharma Ltd LANTHANUM CARBONATE lanthanum carbonate TABLET, CHEWABLE;ORAL 090978-001 Aug 11, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.